MilgoSense

AI-based Diagnostic Tool for Schizophrenia

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in December 2023 by Dovi Kelman, MilgoSense operates with 1–10 employees. The company is currently in its Pre-Funding stage, focusing on developing an AI-based diagnostic tool for schizophrenia.

Business overview

MilgoSense is an early-stage venture in the Health Tech & Life Sciences sector, specifically within digital healthcare and diagnostics. The company is developing a simple, non-invasive, remote, and AI-based diagnostic tool to disrupt the diagnosis, monitoring, and decision-making processes for schizophrenia. This technology aims to address the critical unmet need for an objective decision-support tool to facilitate early diagnosis and treatment, particularly for teenagers, thereby serving the healthcare provider market.

Log in to access full profile

Company Intelligence Q&A

When was MilgoSense founded?
MilgoSense was founded in December 2023.
Who founded MilgoSense?
MilgoSense was founded by Dovi Kelman, who also serves as the CEO.
What is MilgoSense's primary focus?
MilgoSense is focused on developing an AI-based diagnostic tool for schizophrenia, aiming to provide a non-invasive and remote solution for early diagnosis and monitoring.
What problem does MilgoSense aim to solve?
MilgoSense aims to solve the lack of an objective decision-support tool for schizophrenia diagnosis, particularly to help prioritize and bring teenagers in distress to psychiatrists sooner, which can reduce long-term hospitalization and increase independent living.
In which sector does MilgoSense primarily operate?
MilgoSense operates primarily in the Health Tech & Life Sciences sector, with a focus on digital healthcare and diagnostics.
Log in to access full profile